Clinical Scorecard: Comparative Analysis of GLP-1 Receptor Agonists and SGLT2 Inhibitors Versus Monotherapy in Patients with MASLD and Type 2 Diabetes: Insights from Three Target Trial Emulations

At a Glance

Key Highlights

• MASLD affects approximately 32.4% of the global population.
• Patients with MASLD and T2DM have higher rates of hepatic fibrosis progression and cardiovascular mortality.
• Combination therapy of GLP-1 RA and SGLT2i is of significant interest for managing complex cardiometabolic profiles.
• No randomized controlled trials have directly compared GLP-1 RA plus SGLT2i combination therapy versus monotherapy in this population.
• Target trial emulation provides a framework for approximating randomized comparisons from observational data.

Guideline-Based Recommendations

Diagnosis

• Use ICD-10-CM codes K76.0 for NAFLD and K75.81 for NASH for patient identification.

Management

• Consider GLP-1 RA and SGLT2i as treatment options for patients with MASLD and T2DM.

Monitoring & Follow-up

• Evaluate mortality, cardiovascular, and hepatic outcomes over a 5-year follow-up period.

Risks

• Exclude patients with competing liver disease etiologies such as haemochromatosis, alcoholic liver disease, autoimmune hepatitis, or viral hepatitis.

Patient & Prescribing Data

Adults with MASLD and concurrent T2DM.

Combination therapy may provide enhanced benefits compared to monotherapy.

Clinical Best Practices

• Utilize a structured framework for treatment comparisons when RCTs are not feasible.
• Implement regular data quality assessments to ensure compliance and validate data accuracy.

Related Resources & Content

• TriNetX Research Network